secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbCellera Biologics Inc. (ABCL)
CIK:        0001703057
Form:       8-K
Filed at:   2026-07-06T18:53:55+00:00
Accession:  0001703057-26-000037
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbCellera appoints Dr. Lynn Seely to Board of Directors as independent Class III director
--------------------------------------------------------------------------------

- Dr. Lynn Seely appointed as Class III director effective June 30, 2026, serving until 2029 annual meeting.
- She is independent under Nasdaq rules and will receive standard non-employee director compensation.
- Dr. Seely is President and CEO of Lyell Immunopharma, former CEO of Myovant Sciences, and former CMO of Medivation.
- Her experience includes endocrinology, oncology, and women's health, relevant to AbCellera's antibody-based medicine development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703057/000170305726000037/0001703057-26-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703057/000170305726000037/abcl-20260630.htm
  HTML page:      https://secwatch.observer/filing/0001703057-26-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer